The U.S. Patent and Trademark Office (USPTO) is reportedly considering a significant alteration to its patent application protocol. Specifically, the Office is contemplating the addition of a requirement necessitating the filing of terminal disclaimers for overcoming patent examiner rejections predicated on ‘obviousness-type double patenting’.
A recently published report detailed that this move could noticeably alter the organization’s operational approach, particularly pertaining to patents encompassing brand-name drugs. The reactions from the legal realm suggest a mixture of anticipation and concern over the proposed change.
Terminal disclaimers usually come into play when a patentee seeks to establish the distinctiveness between a pair of almost identical inventions. Notably, the practice of filing terminal disclaimers could be impacted as this modification, if implemented, may lead to altering the long-standing processes.
A former USPTO official and legal practitioners have commented that the modification could represent a substantial shift in the agency’s protocol. However, it’s crucial to stay updated on further developments to fully comprehend the potential implications.